Drug intelligence / Profile preview

candesartan cilexetil + rosuvastatin

Development stage
Phase 1
Lead developer
F.P. Clinical Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

**Candesartan cilexetil + rosuvastatin** is a fixed-dose oral combination product consisting of two pharmaceuticals: candesartan cilexetil, an angiotensin II receptor blocker (ARB), and rosuvastatin, a statin that inhibits 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. This combination is indicated for the prevention and management of cardiovascular diseases, including atherosclerosis, hypertension, and hypercholesterolemia. Candesartan cilexetil lowers blood pressure by antagonizing the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone secretion. Rosuvastatin effectively lowers LDL cholesterol and overall cardiovascular risk by inhibiting hepatic cholesterol biosynthesis. The combination aims to synergistically reduce major cardiovascular events and improve patient compliance by simplifying dosing regimens[5][3][7].

Brand names
Sinlip Prevent
Other names
DP-R208DP-R-208DP-R 208
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on candesartan cilexetil + rosuvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on candesartan cilexetil + rosuvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call